Sarepta Therapeutics, Inc. (SRPT)

Sarepta Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	801.28	1,103	428.43	966.78	2,116
Short-Term Investments	138.37	251.78	1,248	1,023	-
Cash & Short-Term Investments	939.65	1,355	1,676	1,989	2,116
Cash Growth	-30.64%	-19.18%	-15.74%	-5.98%	9.15%
Accounts Receivable	502.35	636.6	430.11	256.39	171.64
Other Receivables	17.26	15.1	6.86	5.21	0.01
Receivables	519.61	651.7	436.98	261.6	171.65
Inventory	914.74	749.96	322.86	203.97	186.21
Prepaid Expenses	29.24	32.89	27.64	29.64	30.31
Other Current Assets	134.69	284.13	115.61	73.28	100.06
Total Current Assets	2,538	3,073	2,579	2,558	2,604
Property, Plant & Equipment	470.62	488.65	357.11	244.99	236.69
Long-Term Investments	10.57	136.87	6.53	31.32	34.89
Other Intangible Assets	28.95	26.89	29.62	7.58	14.24
Long-Term Deferred Tax Assets	2.82	2.25	-	-	-
Other Long-Term Assets	298.81	235.05	291.99	286.62	258.06
Total Assets	3,350	3,963	3,265	3,128	3,148
Accounts Payable	280.84	214.44	164.92	95.88	76.74
Accrued Expenses	237.39	246.97	197.93	335.67	206.45
Current Portion of Long-Term Debt	-	-	105.48	-	-
Current Portion of Leases	11.2	-	-	15.49	-
Current Income Taxes Payable	4.76	17.39	13.77	12.52	0.22
Current Unearned Revenue	443.4	130.26	50.42	89.24	89.24
Other Current Liabilities	117.72	122.63	121.15	70.8	80.08
Total Current Liabilities	1,095	731.68	653.66	619.6	452.73
Long-Term Debt	828.97	1,137	1,133	1,544	1,097
Long-Term Leases	199.38	192.47	140.97	57.58	41.51
Long-Term Unearned Revenue	83.91	325	437	485	574.24
Other Long-Term Liabilities	1.53	49.15	41.1	36.94	54.6
Total Liabilities	2,209	2,435	2,405	2,743	2,220
Common Stock	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	6,043	5,739	5,305	4,297	4,135
Retained Earnings	-4,877	-4,211	-4,446	-3,910	-3,207
Treasury Stock	-25.26	-	-	-	-
Comprehensive Income & Other	0.27	-0.22	0.92	-1.66	-0.02
Shareholders' Equity	1,141	1,528	859.34	384.95	928.01
Total Liabilities & Equity	3,350	3,963	3,265	3,128	3,148
Total Debt	1,040	1,330	1,379	1,617	1,138
Net Cash (Debt)	-99.9	25.2	297.29	372.02	977.48
Net Cash Growth	-	-91.53%	-20.09%	-61.94%	12.91%
Net Cash Per Share	-1.00	0.23	3.22	4.25	12.03
Filing Date Shares Outstanding	104.99	97.03	93.86	87.98	87.15
Total Common Shares Outstanding	104.96	96.9	93.73	87.95	87.13
Working Capital	1,443	2,342	1,926	1,938	2,151
Book Value Per Share	10.87	15.77	9.17	4.38	10.65
Tangible Book Value	1,112	1,501	829.72	377.37	913.77
Tangible Book Value Per Share	10.59	15.49	8.85	4.29	10.49
Land	10.17	10.17	10.17	5.18	5.18
Buildings	52.23	51.18	48.06	47.94	47.61
Machinery	152.98	141.98	118.63	102.31	75.04
Construction In Progress	5.58	165.9	91.09	23.59	25.16
Leasehold Improvements	349.73	155.07	99.99	97.33	103.37

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q